Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 7,390 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 10 more
Terminated No phase listed Observational Accepts healthy volunteers

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

NCT05349019
Conditions
Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
Interventions
Observational
Other
Lead sponsor
Escape Bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Culver City, California
Conditions
Metastatic Malignant Melanoma
Interventions
Temozolomide and SU11248
Drug
Lead sponsor
Northern California Melanoma Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
CLN3-related Disorders, Non-CLN3 Related Low Vision
Interventions
OrCam MyEye 2
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Not listed No phase listed Observational Accepts healthy volunteers

Bilateral vs Unilateral CTR

NCT01961011
Conditions
Carpal Tunnel Syndrome
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
St Louis, Missouri
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetrelimab, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Alamitos, California + 3 more
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Oral glucose tolerance test
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
Interventions
Momelotinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of the DryMouth Shield on Snoring

NCT03701165
Conditions
Snoring
Interventions
DryMouth Shield
Device
Lead sponsor
VMS Medical Products, Inc
Industry
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Huntersville, North Carolina
Conditions
COPD, Emphysema or COPD, COPD Exacerbation, COPD Exacerbation Acute, Respiratory Failure, Ventilatory Failure
Interventions
Methylprednisolone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 89 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Hydrops Fetalis, Fetal Growth Retardation
Interventions
Tandem MS test for inborn errors of metabolism
Procedure
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Phoenix, Arizona • Laguna Hills, California • Long Beach, California + 6 more
Conditions
Urinary Bladder Neoplasms
Interventions
Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 19 more
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
16 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Conditions
MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers
Interventions
MK-3475
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
7
States / cities
Stanford, California • Baltimore, Maryland • Bethesda, Maryland + 4 more
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Elimusertib, Gemcitabine
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts
Conditions
Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions
CNP-103, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
45
States / cities
Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more
Conditions
Multiple Myeloma
Interventions
Iberdomide, Elotuzumab, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumor
Interventions
Part 1 ES002023, Part 2 ES002023
Drug
Lead sponsor
Elpiscience Biopharma, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Los Angeles, California + 4 more
Conditions
Heart Block Complete, Heart Block Second Degree
Interventions
Dexamethasone, No Dexamethasone
Drug · Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
350 participants
Timeline
2020 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 9 more
Conditions
Lung Cancer
Interventions
accelerated conformational radiotherapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more
Conditions
Selected Types of Solid Tumor
Interventions
EVM14, Pembrolizumab
Biological · Combination Product
Lead sponsor
Everest Medicines (Beijing) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
New York, New York • Houston, Texas • Fairfax, Virginia
Conditions
Hemophilia B
Interventions
SB-FIX
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions
EO2401, Nivolumab
Biological
Lead sponsor
Enterome
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Interventions
Enfortumab Vedotin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Tampa, Florida